You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

466 Results
Drug
Other Name(s): Arimidex®
Dec 1969
Regimen
Intent: Palliative
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), based on criteria
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Exceptional Access Program
    acalabrutinib - In Combination with Bendamustine and Rituximab for Mantle Cell Lymphoma, based on criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Jan 2026
Drug
Other Name(s): Tecentriq™
Dec 1969
Guidelines and Advice
Updated
Jan 2026
La trousse SEER*Stat du Registre des cas de cancer de l’Ontario contient des fichiers de données anonymisées sur le cancer en Ontario extraits du...
Guidelines and Advice
Status: In-Review
ID: 17-1
Version: 2
Mar 2015
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Regimen

Pages